Roche Holding AG (RHHBY)
| Market Cap | 210.83B |
| Revenue | 66.50B |
| Net Income | 13.60B |
| Shares Out | 6.43B |
| EPS | 1.99 |
| PE Ratio | 16.49 |
| Forward PE | 12.72 |
| Dividend | $1.39 (4.25%) |
| Ex-Dividend Date | Mar 14, 2024 |
| Volume | 2,559,218 |
| Open | 32.56 |
| Previous Close | 32.65 |
| Day's Range | 32.44 - 32.99 |
| 52-Week Range | 29.20 - 40.48 |
| Beta | 0.16 |
| Analysts | Hold |
| Price Target | 40.00 (+21.91%) |
| Earnings Date | n/a |
About RHHBY
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, d... [Read more]
Financial Performance
In 2023, RHHBY's revenue was 60.44 billion, a decrease of -8.16% compared to the previous year's 65.81 billion. Earnings were 12.36 billion, a decrease of -8.67%.
Financial numbers in CHF Financial StatementsAnalyst Forecast
According to one analyst, the rating for RHHBY stock is "Hold" and the 12-month stock price forecast is $40.0.
News
Roche says weight loss drug shows promising results in early trial
The weekly injection helped patients with obesity lose 18.8% of their weight relative to those who received a placebo, after 24 weeks in the phase one trial.
Roche ramps up obesity-drug competition with early-stage trial results
The race to develop powerful new weight-loss drugs grew even more heated on Thursday as Roche Holding AG released early-stage trial results for an experimental obesity treatment.
Roche Climbs After Weight-Loss Drug Shows Efficacy
Roche Holding said its weight-loss drug candidate achieved positive results in an early-stage trial, giving the company a boost in its bid to catch up to Novo Nordisk and Eli Lilly in a class of medic...
Roche shares gain on obesity drug results from early-stage trial
Roche shares gained 4.7% at the market open on Thursday after an early-stage trial showed that the obesity drug candidate by newly acquired Carmot Therapeutics led to significant weight loss.
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib clinical trial of CT-388, a dual G...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
Basel, 16 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase I clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment ...
Roche says FDA approves HPV self-test in US
Swiss drugmaker Roche on Wednesday said the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-testing kit.
Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
Basel, 15 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the FDA approval of its human papillomavirus (HPV) self-collection solution, one of the first available in the United States. Sc...
Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)
SAN DIEGO--(BUSINESS WIRE)--Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision thera...
Roche prepares for business after boom from COVID-related products
Swiss pharmaceutical giant Roche on Wednesday said falling sales of COVID-19 tests and medicines will stop having a “material impact” on its business after the first quarter of 2024 following the end ...
Swiss pharma giant Roche's first-quarter sales edge higher as its emerges from post-Covid-19 slump
Roche lowered its 2024 growth outlook in February as it continues to confront a drop-off in demand for its Covid-19 products and a number of its cancer drugs.
Roche Q1 sales down 6% on forex effect, loss of COVID revenue
Roche said on Wednesday its first-quarter sales slipped 6% as the loss on COVID-19 related revenue was partly offset by further gains in eye drug Vabysmo.
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Roche CEO Thomas Schinecker: “We had a strong start into the year, with both our divisions reporting high single digit growth in their base business – excluding COVID-19 sales. After this quarter, the...
FDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Basel, 19 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumour re...
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecens...
Genentech's Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from the Phase III OCARINA II study (S31.006) of Ocrevus® (ocrel...
Roche's subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Basel, 17 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III OCARINA II study (S31.006) of OCREVUS® (ocrelizumab), an investigational twice-yearly, 10-minute subcu...
David Roche: Israeli escalation against Iran is 'baked in the cake'
David Roche, president and global strategist at Independent Strategy, discusses Iran's drone and missile attack on Israel and says "you have all degrees of escalation that are possible, but escalation...
Genentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall survi...
[Ad hoc announcement pursuant to Art. 53 LR] Roche's Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Basel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or ...
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Basel, 11 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This...
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2.1 Patients with HER2-low status may now be eligible for HER2-targeted treatment, which could significa...
Veracode Embarks on a New Chapter with Appointment of Brian Roche as Chief Executive Officer
BURLINGTON, Mass.--(BUSINESS WIRE)-- #AI--Brian Roche has been appointed CEO at Veracode. His ascension from Chief Product Officer completes a succession plan, which sees Sam King step down.
Lido Advisors' Gina Sanchez offers 3 buys and a bail: Roche, TotalEnergies, AB InBev & Arm
Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss three buys and a bail, including Roche, TotalEnergies, AB InBev, and Arm.